The University of Leicester spinout will put the funding towards recruitment and moving its synthetic antibody operation into larger premises.

MIP Diagnostics, a UK-based synthetic antibody developer spinout from University of Leicester, has closed a £1.5m ($2m) series A round that included Mercia Fund Managers, a unit of investment firm Mercia Technologies. Assorted angel investors, including Andrew Fisher and David Evans, also backed the round. Founded in 2015, MIP is developing polymer-based alternatives to antibodies…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.